Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex | NASDAQ | Healthcare | Biotechnology & Medical Research | US$123.21B | -230x | 2 | US$479.79 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.9% Upside | Upgrade to Pro+ | |
Regeneron Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$74.78B | 18.3x | 1.65 | US$698.74 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36% Upside | Upgrade to Pro+ | |
Lonza Group AG | OTC Markets | Healthcare | Biotechnology & Medical Research | US$45.45B | 67.1x | US$63.15 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.4% Upside | Upgrade to Pro+ | ||
argenx ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | US$37.65B | -917.7x | US$624.67 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.5% Upside | Upgrade to Pro+ | ||
IQVIA Holdings | NYSE | Healthcare | Biotechnology & Medical Research | US$33.29B | 25.2x | 8.84 | US$188.80 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.4% Upside | Upgrade to Pro+ | |
BeiGene ADS | NASDAQ | Healthcare | Biotechnology & Medical Research | US$29.14B | -1.64 | US$271.80 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.2% Upside | Upgrade to Pro+ | ||
BioNTech | NASDAQ | Healthcare | Biotechnology & Medical Research | US$27.07B | -56x | 0.48 | US$112.92 | 3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.7% Upside | Upgrade to Pro+ | |
ICON PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | US$15.35B | 19.9x | 0.67 | US$190.02 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.6% Upside | Upgrade to Pro+ | |
Summit Therapeutics PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | US$15.26B | -59.7x | -1 | US$20.69 | 11.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Insmed | NASDAQ | Healthcare | Biotechnology & Medical Research | US$14.76B | -14.6x | 3.75 | US$81.55 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.7% Upside | Upgrade to Pro+ | |
United Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$14.37B | 13.1x | 0.49 | US$320.05 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.4% Upside | Upgrade to Pro+ | |
Genmab AS | NASDAQ | Healthcare | Biotechnology & Medical Research | US$14.22B | 13.2x | 0.16 | US$22.68 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.7% Upside | Upgrade to Pro+ | |
Moderna | NASDAQ | Healthcare | Biotechnology & Medical Research | US$11.94B | -3.3x | -0.14 | US$30.96 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 45.3% Upside | Upgrade to Pro+ | |
Neurocrine | NASDAQ | Healthcare | Biotechnology & Medical Research | US$11.84B | 34.5x | 1.04 | US$118.72 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39% Upside | Upgrade to Pro+ | |
WuXi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | US$11.83B | -1.83 | US$2.80 | -3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
WuXi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | US$11.83B | 22.9x | -1.83 | US$5.75 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Exelixis | NASDAQ | Healthcare | Biotechnology & Medical Research | US$10.83B | 21.4x | 0.12 | US$38.69 | 2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -1.8% Downside | Upgrade to Pro+ | |
Sarepta | NASDAQ | Healthcare | Biotechnology & Medical Research | US$10.34B | 44x | 0.31 | US$106.75 | 3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Medpace Holdings | NASDAQ | Healthcare | Biotechnology & Medical Research | US$9.97B | 25x | 0.58 | US$327.32 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.5% Upside | Upgrade to Pro+ | |
Bio-Techne | NASDAQ | Healthcare | Biotechnology & Medical Research | US$9.76B | 61.5x | -2.09 | US$61.75 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40% Upside | Upgrade to Pro+ | |
Tempus AI | NASDAQ | Healthcare | Biotechnology & Medical Research | US$9.67B | -8.9x | 0.27 | US$56.18 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.7% Upside | Upgrade to Pro+ | |
Vaxcyte | NASDAQ | Healthcare | Biotechnology & Medical Research | US$9.40B | -19.2x | -2.49 | US$73.02 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascendis Pharma AS | NASDAQ | Healthcare | Biotechnology & Medical Research | US$9.37B | -22.1x | -1.01 | US$156.58 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.5% Upside | Upgrade to Pro+ | |
EXACT Sciences | NASDAQ | Healthcare | Biotechnology & Medical Research | US$8.81B | -40.1x | 0.02 | US$47.41 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47.6% Upside | Upgrade to Pro+ | |
Charles River Laboratories | NYSE | Healthcare | Biotechnology & Medical Research | US$8.45B | 824.4x | -8.39 | US$165.31 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.3% Upside | Upgrade to Pro+ | |
Qiagen | NYSE | Healthcare | Biotechnology & Medical Research | US$8.30B | 102.8x | -1.3 | US$38.40 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.2% Upside | Upgrade to Pro+ | |
Revolution Med | NASDAQ | Healthcare | Biotechnology & Medical Research | US$7.57B | -11.4x | -1.74 | US$40.74 | 4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Madrigal Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$7.54B | -15.3x | 1.7 | US$341.27 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.2% Upside | Upgrade to Pro+ | |
Legend Bio | NASDAQ | Healthcare | Biotechnology & Medical Research | US$6.42B | -18.1x | -0.52 | US$35.01 | -4.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Blueprint Medicines Corp | NASDAQ | Healthcare | Biotechnology & Medical Research | US$6.17B | -89.2x | -1.05 | US$96.57 | 6.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.6% Upside | Upgrade to Pro+ | |
Telix Pharmaceuticals ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.82B | 210.1x | 0.24 | US$17.98 | -4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.8% Upside | Upgrade to Pro+ | |
Verona Pharma ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.70B | -31.1x | 0.19 | US$69.63 | 3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.4% Upside | Upgrade to Pro+ | |
Alkermes Plc | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.58B | 15.4x | 4.32 | US$34.33 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.7% Upside | Upgrade to Pro+ | |
Cytokinetics Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.43B | -9x | -2.68 | US$46 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nuvalent | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.37B | -18.8x | 0.25 | US$74.98 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 46.7% Upside | Upgrade to Pro+ | |
Ionis Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.28B | -13.3x | 0.62 | US$33.19 | 5.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Krystal Biotech | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.16B | 59.8x | 0.09 | US$179.25 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.9% Upside | Upgrade to Pro+ | |
SpringWorks | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.33B | -16.5x | -0.52 | US$57.76 | 8.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.7% Upside | Upgrade to Pro+ | |
TG | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.32B | -299.1x | -6.51 | US$30.09 | 5.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47.9% Upside | Upgrade to Pro+ | |
Ultragenyx | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.97B | -6.7x | -0.29 | US$42.92 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Crispr Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.77B | -10x | 0.08 | US$43.92 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biohaven Pharma | NYSE | Healthcare | Biotechnology & Medical Research | US$3.76B | -4.2x | 0.14 | US$37.18 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Akero Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.74B | -12.7x | 0.49 | US$49.12 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Scholar Rock | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.68B | -15x | 1.12 | US$38.82 | 7.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.8% Upside | Upgrade to Pro+ | |
Arcellx | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.51B | -30.6x | 0.9 | US$64.82 | 5.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Immunovant | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.50B | -7.8x | 0.21 | US$20.60 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Rhythm Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.43B | -12.6x | 0.37 | US$54.91 | 3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.4% Upside | Upgrade to Pro+ | |
Alvotech | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.43B | -7.2x | -0.22 | US$11.36 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Crinetics Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.32B | -9x | US$35.78 | 7.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
ACADIA | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.26B | 14.2x | 0.03 | US$19.60 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.1% Upside | Upgrade to Pro+ |